About BioCryst
BioCryst is a company based in Durham (United States) founded in 1986. The company has 580 employees as of December 31, 2024. BioCryst has completed 1 acquisition, including Astria Therapeutics. BioCryst offers products and services including Oral Small-Molecule Therapeutics and Protein Therapeutics. BioCryst operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others.
- Headquarter Durham, United States
- Employees 580 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Biocryst Pharmaceuticals, Inc.
-
Annual Revenue
$450.71 M (USD)36as on Dec 31, 2024
-
Net Profit
-$88.88 M (USD)60.77as on Dec 31, 2024
-
EBITDA
-$1.3 M (USD)98.73as on Dec 31, 2024
-
Latest Funding Round
$350 M (USD), Post-IPO
Nov 22, 2021
-
Investors
Kleiner Perkins
& 8 more
-
Employee Count
580
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of BioCryst
BioCryst is a publicly listed company on the NASDAQ with ticker symbol BCRX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of BioCryst
BioCryst offers a comprehensive portfolio of products and services, including Oral Small-Molecule Therapeutics and Protein Therapeutics.
Treatments for rare diseases like hereditary angioedema.
Innovative proteins targeting rare disease conditions.
People of BioCryst
Unlock access to complete
Unlock access to complete
Leadership Team
62 people
Operations Team
21 people
Software Development Team
17 people
Product Management Team
16 people
Legal and Compliance
12 people
Sales and Marketing
10 people
Human Resources and Administration
8 people
Rare Team
7 people
Unlock access to complete
Funding Insights of BioCryst
Investors in BioCryst
BioCryst has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Kleiner Perkins, Royalty Pharma and TPG.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made in marketed and late-stage biopharmaceutical companies.
|
Locked | Locked | Locked | |
|
Global private equity investments are managed by the firm.
|
Locked | Locked | Locked | |
|
Private debt funds are managed across multiple sectors.
|
Locked | Locked | Locked |
Investor details for BioCryst
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by BioCryst
BioCryst has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Astria Therapeutics.
Investment portfolio details for BioCryst
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Therapeutics for rare diseases, including hereditary angioedema inhibitors, are developed.
|
Locked | Locked | 2008 | Locked |
Complete acquisition details for BioCryst
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - BioCryst
Detailed financials for BioCryst
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Biocryst Comparisons
Peer comparison for BioCryst
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of BioCryst
BioCryst operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| Locked | Locked | Locked |
Developer of drugs for treating rare and autoimmune diseases
|
|
| Locked | Locked | Locked |
Small molecule drugs for rare diseases are developed.
|
Detailed competitors of BioCryst
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Biocryst
Complete news archive for BioCryst
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BioCryst
BioCryst was founded in 1986 and raised its 1st funding round 21 years after it was founded.
BioCryst is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
Jon Stonehouse is the current CEO of BioCryst.
As of Dec 31, 2024, the latest employee count at BioCryst is 580.
Annual revenue of BioCryst is $450.71M as on Dec 31, 2024.
BioCryst was founded in 1986 and is based in Durham, United States, within the biotechnology sector. Small molecule therapeutics are developed for orphan and autoimmune conditions, alongside antiviral agents. Operations focus on pipeline candidates such as BCX7353, targeted at hereditary angioedema, and BCX4430 (Galidesivir), a broad-spectrum antiviral for hemorrhagic fevers including SARS-CoV-2. RAPIVAB is also offered for influenza treatment.
BioCryst's top competitors include Moderna, Spark Therapeutics and BridgeBio.
BioCryst offers Oral Small-Molecule Therapeutics and Protein Therapeutics.
Yes, BioCryst is publicly traded on NASDAQ under the ticker symbol BCRX.
BioCryst has made 1 acquisition, including Astria Therapeutics.
BioCryst has 9 investors. Key investors include Kleiner Perkins, Royalty Pharma, TPG, Orbimed, and MidCap Financial.
The ticker symbol of BioCryst is BCRX on NASDAQ.